These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11340368)

  • 1. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.
    Adler G; Brassen S
    Neuropsychobiology; 2001; 43(4):273-6. PubMed ID: 11340368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
    Brassen S; Adler G
    Pharmacopsychiatry; 2003 Nov; 36(6):304-8. PubMed ID: 14663655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Schölzel-Dorenbos CJ
    Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117
    [No Abstract]   [Full Text] [Related]  

  • 4. Brief review: rivastigmine, a second cholinesterase inhibitor.
    Patterson C; Hogan DB
    Can J Neurol Sci; 2001 Feb; 28 Suppl 1():S122-3. PubMed ID: 11237306
    [No Abstract]   [Full Text] [Related]  

  • 5. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of treatment response to rivastigmine in Alzheimer's dementia.
    Adler G; Brassen S; Chwalek K; Dieter B; Teufel M
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):292-4. PubMed ID: 14742608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.
    Fogelson N; Kogan E; Korczyn AD; Giladi N; Shabtai H; Neufeld MY
    Acta Neurol Scand; 2003 Apr; 107(4):252-5. PubMed ID: 12675697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
    Linkins KW; Lloyd JR; Hjelmstad GO; Strausbaugh HJ
    Pharmacoeconomics; 2000 Dec; 18(6):609-12. PubMed ID: 11227398
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
    McMillan H
    Int J Geriatr Psychiatry; 1999 Dec; 14(12):1078-9. PubMed ID: 10607978
    [No Abstract]   [Full Text] [Related]  

  • 10. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract]   [Full Text] [Related]  

  • 11. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
    Rombouts SA; Barkhof F; Van Meel CS; Scheltens P
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):665-71. PubMed ID: 12438467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivastigmine (Exelon) for Alzheimer's disease.
    Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
    [No Abstract]   [Full Text] [Related]  

  • 14. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
    Hauber AB; Gnanasakthy A; Mauskopf JA
    Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
    Casademont J; Miró O; Rodriguez-Santiago B; Viedma P; Blesa R; Cardellach F
    J Neurol Sci; 2003 Jan; 206(1):23-6. PubMed ID: 12480080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.
    Alagiakrishnan K; Sclater A; Robertson D
    J Am Geriatr Soc; 2003 Sep; 51(9):1326. PubMed ID: 12919253
    [No Abstract]   [Full Text] [Related]  

  • 19. Understanding changes in cholinergic function: implications for treating dementia.
    J Clin Psychiatry; 2002 Mar; 63(3):259-69. PubMed ID: 11926730
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    Bullock R
    Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.